TROP2 antibody drug with anti–PD-1 for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer that has not responded to standard treatment
- Your cancer must be confirmed from tumor cells or tissue under a microscope
- You have measurable tumors on scans (per RECIST or brain-scan criteria, if relevant)
- You can and are willing to provide tumor tissue, either old stored tissue or a biopsy before treatment
- You can do at least one blood/organ check and have the required blood counts and liver function
- Your general health is good enough (ECOG 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
This study tests a new drug called Trop2-ADC, either alone or combined with immunotherapy, for people with advanced triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a medicine called TROP2-ADC, which targets a protein on cancer cells to kill them. It is for people with advanced high-grade neuroendocrine tumors that have not responded to standard treatments. The goal is to see if this drug can shrink tumors or slow their growth.
This trial tests a new treatment called Trop2 CAR-NK, which uses your own immune cells modified to attack lung cancer cells that have a protein called Trop2. It is for people with advanced non-small cell lung cancer that has not responded to standard therapies.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.